Alliance for Pandemic Preparedness
January 29, 2021
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
Category: Article Summary
Topic: Vaccines and Immunity
Keywords (Tags): vaccines, variants
[Pre-print, not peer-reviewed] Using a lentivirus-based pseudovirus assay, the SARS-CoV-2 B.1.1.7 (UK) variant was shown to exhibit only modestly reduced susceptibility to neutralization from convalescent sera (1.5-fold average reduction) and sera from recipients of both the Moderna and Novavax vaccine phase 1 studies (2-fold average reduction after two inoculations. The authors used the prototypic D614G variant as a comparator.
Cheng et al. (Jan 28, 2021). SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. Pre-print downloaded Jan 29 from